Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 176 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Seizure, Partial Clear all
Completed Phase 3 Interventional Results available

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

NCT00150800
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB PHARMA Inc. (US)
Industry
Eligibility
16 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 23, 2026, 10:58 PM EDT
Withdrawn Phase 2 Interventional

Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy

NCT00982787
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Botanical extract from Passiflora incarnata
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Jul 23, 2026, 10:58 PM EDT
Recruiting Phase 2 Interventional

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407
View directory record Official record
Conditions
Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
Interventions
RAP-219
Drug
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Boise, Idaho • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

NCT02849626
View directory record Official record
Conditions
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
29
States / cities
Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 23, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional Results available

Buspirone Therapy for Localized Epilepsy

NCT01496612
View directory record Official record
Conditions
Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy, Depression
Interventions
Buspirone, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

NCT01728077
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
16 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

NCT01161524
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Aurora, Colorado • Gulf Breeze, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jul 23, 2026, 10:58 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

NCT07233239
View directory record Official record
Conditions
Focal Seizures
Interventions
CBD-OS
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

NCT00955357
View directory record Official record
Conditions
Partial Epilepsies
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
17 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
40
States / cities
Irvine, California • Rancho Mirage, California • Clearwater, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 3 Interventional

Pediatric Epilepsy Study

NCT00050934
View directory record Official record
Conditions
Epilepsy, Epilepsies, Partial
Interventions
oxcarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 3 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Jul 23, 2026, 10:58 PM EDT
Withdrawn Phase 3 Interventional

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

NCT03108729
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Henderson, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Jul 23, 2026, 10:58 PM EDT
Recruiting Phase 2Phase 3 Interventional

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

NCT06999902
View directory record Official record
Conditions
Focal Seizure
Interventions
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Phoenix, Arizona • DeLand, Florida • Miami Lakes, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

NCT00151879
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 3 Interventional

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

NCT00056576
View directory record Official record
Conditions
Epilepsy, Complex Partial
Interventions
Zonisamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
16 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Jul 23, 2026, 10:58 PM EDT
Withdrawn Not applicable Interventional

Turmeric as Treatment in Epilepsy

NCT03254680
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, Focal Seizures
Interventions
Turmeric
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Not applicable Interventional

Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

NCT04770337
View directory record Official record
Conditions
Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Interventions
STARSTIM device, Sham Device
Device
Lead sponsor
Neuroelectrics Corporation
Industry
Eligibility
9 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

NCT00310375
View directory record Official record
Conditions
Epilepsy
Interventions
Ezogabine: USAN Retigabine (International Nonproprietary Name)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
30
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

NCT00464269
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

NCT00368472
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Jul 23, 2026, 10:58 PM EDT
Recruiting Phase 3 Interventional

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

NCT05716100
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
XEN1101, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
19
States / cities
Little Rock, Arkansas • Downey, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Not applicable Interventional

The Effect of Music Periodicity on Interictal Epileptiform Discharges

NCT01515436
View directory record Official record
Conditions
Rolandic Epilepsy, Benign Childhood Epilepsy With Centrotemporal Spikes, Epilepsy, Seizures
Interventions
Mozart alternating with Beethoven, Beethoven alternating with Mozart
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
5 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Jul 23, 2026, 10:58 PM EDT
Enrolling by invitation Phase 3 Interventional

An Open-label Study of XEN1101 in Epilepsy

NCT05718817
View directory record Official record
Conditions
Focal Epilepsy, Tonic-Clonic Seizures
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
54
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 3 Interventional

Early Surgical Intervention to Treat Epilepsy

NCT00040326
View directory record Official record
Conditions
Epilepsy, Epilepsy, Temporal Lobe, Seizures
Interventions
anteromesial temporal resection, antiepileptic drugs
Procedure · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Jul 23, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

NCT00772603
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Placebo, 2400mg SPN-804, 1200mg SPN-804
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Jul 23, 2026, 10:58 PM EDT